Leucid Bio, a biotech company, announced on Thursday that it has signed a first-of-its-kind commercial manufacturing master services agreement with Great Ormond Street Hospital NHS Foundation Trust (GOSH).

The commercial manufacturing master services agreement has been signed to produce lead asset, LEU011, a lateral CAR targeting NKG2D ligands, for use in human clinical studies.

Leucid Bio is expected to file its Clinical Trial Application (CTA) to commence the clinical trial in the first half of 2023, and will be dosing subjects suffering from solid tumours and haematological malignancies by the second half of 2023, subject to regulatory approval.

According to the terms of the contract, both firms will work at the Zayed Centre for Research into Rare Disease in Children on the LEU011 first-in-man study, and potentially, other Leucid clinical programmes. Each company is to retain ownership of background IP, and Leucid, subject to contractual obligations, is to own all Intellectual Property Rights resulting from the Manufacturing Services performed.